# Novavita Thera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/novavita-thera

- Industry: Biotechnology
- Headquarters: Rochester, US
- Website: www.cytotheryx.com
- Total disclosed funding: $60M
- Latest round: Series A (Jan 12, 2026)
- Investors on record: 1

## About

Founded in 2019 and based in Minnesota, US, Novavita Thera, Inc., formerly known as Cytotheryx, Inc. operates as a preclinical gene therapy company focused on liver and metabolic diseases. The CEO of the company is John R. Swart. In January 2026,?Cytotheryx, Inc.?raised?USD 60 million?in?series A funding?from investor Ouroboros Group through Ouroboros Family Founders Fund I, LP. The funding is a part of a larger Series A round.

Novavita Thera, Inc. develops a bioincubator for primary human hepatocytes, or liver cells to provide access to the human liver cells required to advance disease-specific research. The company's bioincubator also provides the tools needed to develop new applications for drug delivery, cell and gene therapies, liver assist devices, and allotransplantation.

The company will use the January 2026 funds to expand real-estate footprint, scale GMP manufacturing capacity, and support operational growth, accelerating development and readiness of its liver cell therapy platform while remaining non-dilutive.

## Funding rounds

- Series A, Jan 12, 2026, $60M — Ouroboros Group

## Investors

- Ouroboros Group (https://capitalatlas.ai/funds/ouroboros-group) — Series A